Skip to main content
. 2019 Oct 24;47(22):11623–11636. doi: 10.1093/nar/gkz1004

Figure 1.

Figure 1.

KDM4B promotes AR-V7 expression. (A) Relative fold change of mRNAs of AR-V7 and AR in PCa cells transfected with KDM4B (4B) or mutant KDM4BH188A (4Bm) expression plasmid. mRNA was normalized against internal Calnexin and expressed relative to that of vector transfected cells (n = 3, mean ± SEM). (B) WB of indicated proteins in LNCaP-ctl, LNCaP-4B and VCaP cells. Antibody against N-terminal AR (SP107) was used to detect both AR and AR-V7. (C) WB of AR-V7 and AR in LNCaP-4B cells cultured in CFBS in the absence or presence of bicalutamide (bic, 10 μM) or enzalutamide (enz, 5 μM). (D) The mRNA and (E) protein levels of AR-V7 and AR in VCaP and 22Rv1 cells transfected with control (ctl) or KDM4B siRNAs. mRNA was normalized against internal Calnexin and expressed relative to that of control siRNA-transfected cells (n = 3, mean ± SEM). (F) WB of KDM4B, AR-V7 and AR in clonal 22Rv1 cells transfected with control (ctl) or KDM4B-targeted gRNA (cl4 and cl7). GAPDH was used as loading control. (G) WB of AR-V7 and AR in 22Rv1 cells treated with vehicle (veh) or KDM4 inhibitor B3. (H) Spearman's correlation coefficient analysis between mRNAs of KDM4B and AR-V7 from the SU2C database.